Send a Tweet
Most Popular Choices
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Tell A Friend Printer Friendly Page Save As Favorite View Favorites
General News

Oh That? Seroquel Marketing Undeterred by This Week's Deceptive Marketing Settlement

By       Message Martha Rosenberg       (Page 1 of 2 pages)     Permalink    (# of views)   2 comments

Related Topic(s): ; ; ; ; ; ; ; ; ; , Add Tags
Add to My Group(s)

Must Read 1   Supported 1   Valuable 1  
View Ratings | Rate It

opednews.com Headlined to H4 3/15/11

Author 1353
Become a Fan
  (83 fans)
- Advertisement -


Google the word "depression" and the first search result you'll get is for the antipsychotic Seroquel XR.

 

Visit WebMD and the home page hosts similar ads for Seroquel XR, above and adjacent to the lead news story.

- Advertisement -

 

Who would know AstraZeneca inked the largest multi-state consumer protection settlement on record relating to deceptive Seroquel marketing just this week? For $68.5 million? Only a year after inking a similar settlement related to burying side effect and safety information for $520 million with the government?

- Advertisement -


Borison Arrives at Club Fed
(Image by Martha Rosenberg)
  Permission   Details   DMCA

 

Who would know AstraZeneca has already settled nearly 25,000 personal injury lawsuits pertaining to Seroquel with more to come says ABC news?

 

First approved in 1997, Seroquel has enjoyed the camel-nose-under-the-tent phenomenon known as indications creep. First approved for schizophrenia, it was later approved for bipolar disorder and psychiatric conditions in children. But it was Seroquel's 2009 approval as an add-drug for depression that helped it reach its spectacular sales of $5.3 billion in 2010 thanks to the US' walloping depression "market" of 20 million.

- Advertisement -

 

Seroquel's blood sugar, weight gain and heart side effects are well known. That's why FDA regulators opposed its use as a first choice, stand-alone treatment for the 10 percent of the US population with depression when safer drugs exist. "I saw no clear advantage demonstrated in efficacy," said Dr. Wayne Goodman who chaired the FDA panel considering the depression indication. "There were side effects, and I would expect unintended consequences associated with wide-scale use of the drug."

 

The drug also can cause increased mortality in elderly patients with dementia-related psychosis, suicidality, neuroleptic malignant syndrome, cataracts, seizures, increases in blood pressure and movement disorders in neonates when their mothers take it.

Next Page  1  |  2

 

- Advertisement -

Must Read 1   Supported 1   Valuable 1  
View Ratings | Rate It

opednews.com

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)
 

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon Share Author on Social Media   Go To Commenting

The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

It's the Cymbalta Stupid

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too